胰高血糖素样肽-1及其受体激动剂治疗2型糖尿病的研究进展

Research Progress of Glucagon-like Peptide-1 and Its Receptor Agonists for Type 2 Diabetes Mellitus

胰高血糖素样肽-1(Glucagon-like peptide-1,GLP-1)是小肠L细胞分泌的一种内源性活性多肽,以葡萄糖依赖的方式促进胰岛素分泌,具有降低血糖作用。与口服糖尿病治疗药物相比,GLP-1优点突出:控制血糖效果良好,可避免低血糖的发生、保护胰岛β细胞功能等。因此,以GLP-1为研究对象,开发糖尿病治疗药物具有良好的前景。本文就笔者在长效多肽GLP-1受体激动剂的研究过程中就胰高血糖素样肽-1及其受体激动剂治疗2型糖尿病的研究进展进行了阐述,为后续的进一步开发研究提供了思路。

Glucagon-like peptide-1( GLP-1) is an endogenous active peptide secreted by small intestine L cells and promotes insulin secretion in a glucose-dependent manner with a hypoglycemic effect. Compared with oral diabetes treatment, GLP-1 has the following advantages : good blood sugar control, avoidance of hypoglycemia, protection of pancreatic β-cell function and etc. Therefore, taking GLP-1 as the research object, development of diabetes therapeutic drugs has a good prospect. In this paper, the authors have described the process of research on glucagon-like peptide-1 and its receptor agonist for the treatment of type 2 diabetes mellitus for further follow-up study.